New drugs: pitavastatin calcium, vigabatrin, and romidepsin.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA, USA.
Christian
Mary Elizabeth
ME
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047630:Depsipeptides / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004348:Drug Labeling; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy; D007223:Infant; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy; D013036:Spasms, Infantile / Q000188:drug therapy; D020888:Vigabatrin / Q000009:adverse effects / Q000627:therapeutic use*
D000927:Anticonvulsants; D000970:Antineoplastic Agents; D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; C087123:romidepsin; D020888:Vigabatrin; C108475:pitavastatin